Caxton Corp is an investment fund managing more than $17.6 billion ran by Heath Weisberg. There are currently 11 companies in Mr. Weisberg’s portfolio. The largest investments include Xeris Biopharma Inc and Rezolute Inc, together worth $14.7 billion.
As of 8th May 2024, Caxton Corp’s top holding is 5,113,348 shares of Xeris Biopharma Inc currently worth over $11.3 billion and making up 64.4% of the portfolio value.
Relative to the number of outstanding shares of Xeris Biopharma Inc, Caxton Corp owns more than approximately 0.1% of the company.
In addition, the fund holds 1,318,967 shares of Rezolute Inc worth $3.36 billion.
The third-largest holding is Spdr S&p 500 Etf Tr worth $971 million and the next is Berkshire Hathaway worth $428 million, with 1,019 shares owned.
Currently, Caxton Corp's portfolio is worth at least $17.6 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Caxton Corp office and employees reside in Princeton, New Jersey. According to the last 13-F report filed with the SEC, Heath Weisberg serves as the Chief Compliance Officer at Caxton Corp.
In the most recent 13F filing, Caxton Corp revealed that it had opened a new position in
Spdr S&p 500 Etf Tr and bought 1,856 shares worth $971 million.
On the other hand, there are companies that Caxton Corp is getting rid of from its portfolio.
Caxton Corp closed its position in Savara Inc on 15th May 2024.
It sold the previously owned 4,980,804 shares for $16 billion.
Heath Weisberg also disclosed a decreased stake in Xeris Biopharma Inc by approximately 0.1%.
This leaves the value of the investment at $11.3 billion and 5,113,348 shares.
The two most similar investment funds to Caxton Corp are Ares Management and Jarislowsky, Fraser Ltd. They manage $17.5 billion and $17.4 billion respectively.
Caxton Corp’s portfolio is diversified across 3 sectors.
Currently, their heaviest sector is Health Care — making up 66.1% of
the total portfolio value.
The fund focuses on investments in the United States as
27.3% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
9% of the total holdings value.
On the other hand, small-cap stocks make up only 9.1% of the portfolio.
The average market cap of the portfolio companies is close to $225 billion.
These positions were updated on May 15th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Savara Inc |
Closed
4,980,804
|
$16,026,005,000 | |
| Xeris Biopharma Holdings Inc |
9.37%
5,113,348
|
$11,300,499,000 | 64.38% |
| Rezolute Inc |
No change
1,318,967
|
$3,363,366,000 | 19.16% |
| Molecular Templates Inc |
Closed
2,052,991
|
$985,436,000 | |
| Spdr S&p 500 Etf Tr |
Opened
1,856
|
$970,988,000 | 5.53% |
| Berkshire Hathaway Inc. |
Opened
1,019
|
$428,308,000 | 2.44% |
| Kyverna Therapeutics Inc |
Opened
15,846
|
$393,614,000 | 2.24% |
| Molecular Templates Inc |
Opened
136,866
|
$306,580,000 | 1.75% |
| Mind Medicine Mindmed Inc |
Opened
29,065
|
$273,207,000 | 1.56% |
| Abivax Sa |
Opened
15,808
|
$226,055,000 | 1.29% |
| Lexeo Therapeutics Inc |
Opened
10,319
|
$161,796,000 | 0.92% |
| Compass Therapeutics Inc |
0.00%
43,465
|
$86,062,000 | 0.49% |
| Allakos Inc |
Closed
17,733
|
$77,318,000 | |
| Adicet Bio Inc |
Opened
17,488
|
$41,096,000 | 0.23% |
| Elevation Oncology Inc |
Closed
21,725
|
$33,022,000 | |
| No transactions found | |||
| Showing first 500 out of 15 holdings | |||